Biography/Memoir

Depression: the psychedelic cure

They’ve raised roughly $20 million for their company from some extremely savvy investors.

George Goldsmith and Katya Malievskaia are a married couple whose startup – Compass Pathways – will soon launch the largest triple-blind clinical trial ever of a psychedelic drug. The drug is psilocybin, which is the active ingredient in psychedelic mushrooms. And the condition is treatment-resistant depression. This awful malady plagues over a hundred million people worldwide. And as the term “treatment-resistant” implies, it lacks a cure. Now, if that sounds a bit implausible, consider who George and Katya have drawn to their company. Their Board of Directors includes Thomas Lonngren, who spent ten years running Europe’s equivalent of the FDA (the European Medicines Agency). Also on their board is the former Chief Medical Officer of Bristol Meyers Squibb – one of the world’s largest pharmaceutical companies. As you’ll learn from our conversation, Katya & George are both deeply experienced in medical research. They’re perhaps even more plugged into drug approval process, and have designed their trial in consultation with the top drug regulators of multiple countries. The full interview is right here : HERE

From the Article:
Depression: the psychedelic cure & Afteron
Artwork Fair Use by: ECfES

Sound off : on Kratom

…overdoses spike climbs to 23

…shares his story…

Leave a Reply